Navigation Links
RELAX-AHF: Poor diuretic response associated with worse clinical outcomes

Athens, 17 May 2014: Poor diuretic response is associated with worse in-hospital and post-discharge clinical outcomes, results of the RELAX-AHF trial reveal. The study also found that serelaxin has a neutral effect on diuretic response.

These novel data from the RELAX-AHF trial were presented by lead author Professor Adriaan A. Voors at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

RELAX-AHF was a double blind, placebo-controlled trial of 1161 patients admitted to hospital with acute heart failure. Patients were randomised to receive 48-hour infusions of placebo or serelaxin (30g/kg per day) within 16 hours from presentation. Primary analysis of the study showed that serelaxin reduced dyspnoea and decreased 180 day mortality.1

The current substudy, presented for the first time today, had two aims. The first was to confirm preliminary findings of the PROTECT trial, which found that poor diuretic response is a serious clinical problem.2 The second was to investigate whether the beneficial effects of serelaxin discovered in the primary analysis were related to improvement of the diuretic response.

Diuretic response was defined as kilograms of weight loss per 40mg of the loop diuretic furosemide. Professor Voors said: "Congestion is the main problem in patients with acute decompensated heart failure and we give them loop diuretics to get rid of the excess fluid. Patients who respond to the loop diuretic have diuresis and lose weight. But a substantial proportion do not respond to the diuretic, do not diurese and do not lose weight."

He added: "Diuretic response could be measured by urinary output but when patients no longer need a catheter it is difficult to capture how much fluid they have lost. We therefore used weight loss as a more objective and reliable measurement of diuretic response. The more weight patients lost per mg of furosemide given, the better their diuretic response."

The study found that diuretic response was an important clinical problem, confirming preliminary results from the PROTECT trial. Patients with a poor diuretic response had less dyspnoea relief (p=0.0001) and a higher risk of cardiovascular death or rehospitalisation for heart failure or renal failure through day 60 (p<0.004). Poor diuretic response was not associated with increased 180-day cardiovascular mortality (p=0.546).

Professor Voors said: "The most important message from this substudy is that if patients are hospitalised for acute heart failure and do not respond well to their diuretic then they are in trouble. Their recovery in hospital is likely to be worse and when they are sent home there is a good chance that they will be rehospitalised again or even die."

The next question was whether serelaxin influenced patients' response to diuretics. The researchers found that serelaxin had no effect on diuretic response. Patients in the serelaxin group improved clinically and were given fewer diuretics but they lost less weight than the placebo group.

Professor Voors said: "Patients felt better with serelaxin and so physicians gave them less diuretics. But these patients did not diurese more, so the overall effect of serelaxin on diuretic response was neutral."

He added: "We will continue to look for the mechanisms by which serelaxin exerts its positive effects. The current study shows that the beneficial effects of serelaxin are not through improvement of diuretic response. We have already shown that serelaxin prevents the organ damage that occurs during an episode of acute heart failure3 and we will continue to investigate other modes of action."

Professor Voors concluded: "The major finding from this substudy of the RELAX-AHF trial is that diuretic resistance is a clinical problem that leads to worse in-hospital and early post-discharge clinical outcomes in patients with acute heart failure. More insights are needed into the problem of poor diuretic response so that better therapies can be found to improve the diuretic response and improve clinical outcomes."


Contact: Jacqueline Partarrieu
European Society of Cardiology

Related medicine news :

1. Black patients with hypertension not prescribed diuretics enough
2. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
3. Response to First Treatment May Predict Epilepsys Course
4. Genetic predictor of breast cancer response to chemotherapy
5. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
6. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
7. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
8. Babies susceptibility to colds linked to immune response at birth
9. Biomarker predicts response to cancer treatment
10. Baseline characteristics of children with mild persistent asthma predict response to ICS
11. Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
Post Your Comments:
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
(Date:11/24/2015)... , ... November 24, 2015 , ... DMG Productions announced ... Begley Jr., airing first quarter 2016 via Discovery Channel. Dates and show times TBA. ... Province, and is in the business of producing and supplying medical marijuana pursuant to ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Trustees, Massachusetts’ largest ... and parking fees at several of their most popular properties, including Crane Beach ... support of REI’s Black Friday #OptOutside Campaign. The Trustees encourage families and friends ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... ... With Thanksgiving right around the corner, holiday travel season is about to ... and vehicle. , According to the National Highway Traffic Safety Administration, 301 people were ... following safety tips from the NHTSA: , Inspect ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... bekanntgegeben, dass sie eine Lizenz für das Patent über ... CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben ... FUI AAP8 ins Leben gerufenen und von Edelris gemeinsam ... FXR als ein Behandlungsziel für HBV identifiziert, und es ...
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
Breaking Medicine Technology: